Jennifer Fulk - 08 Sep 2026 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Reporting relationship: Chief Financial Officer
Issuer ticker: KURA
Reported as of: 08 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Sep 2026, 16:30:03 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: Teresa Bair, Attorney-in-fact for Jennifer Fulk

Key filing fact

Jennifer Fulk filed Form 4 for Kura Oncology, Inc. (KURA) on 10 Sep 2026.

Key facts

This page summarizes Jennifer Fulk's Form 4 filing for Kura Oncology, Inc. (KURA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Sep 2026, 16:30.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001873522 Primary reporting owner

Fulk Jennifer

Relationship: Chief Financial Officer
Address: C/O KURA ONCOLOGY, INC., 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO
Signature: Teresa Bair, Attorney-in-fact for Jennifer Fulk
Signature date: 10 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KURA transaction Derivative

Option to purchase common stock

Award

Transaction value
Shares: +450,000
Change %
Price: $0.000000^*
Shares after: 450,000
Date: 08 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 450,000
Exercise price: $12.52
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

1/4th of the shares vest on the one year anniversary of the vesting commencement date, and 1/48th of the shares vest in 36 monthly installments thereafter.